Cargando…

AB064. The efficacy of UroLift in Korean men with benign prostatic hyperplasia: preserving sexual function and improving lower urinary tract symptoms

BACKGROUND: Prostatic urethral lift (PUL) using UroLift is new and promising in the treatment of men with lower urinary tract symptoms (LUTS). It has been recently released for clinical use in Korea. This study is to report the initial experience and outcomes of the METHODS: Between December 2016 an...

Descripción completa

Detalles Bibliográficos
Autores principales: Tae, Sun, Moon, Du Geon, Kim, Je Jong, Kim, Sang Woo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6186654/
http://dx.doi.org/10.21037/tau.2018.AB064
_version_ 1783362872529649664
author Tae, Sun
Moon, Du Geon
Kim, Je Jong
Kim, Sang Woo
author_facet Tae, Sun
Moon, Du Geon
Kim, Je Jong
Kim, Sang Woo
author_sort Tae, Sun
collection PubMed
description BACKGROUND: Prostatic urethral lift (PUL) using UroLift is new and promising in the treatment of men with lower urinary tract symptoms (LUTS). It has been recently released for clinical use in Korea. This study is to report the initial experience and outcomes of the METHODS: Between December 2016 and November 2017, 31 patients with LUTS due to benign prostatic hyperplasia (BPH) either who were high risk for anesthesia, or wanting to preserve their sexual function, were treated with PUL. Patients were followed up for 3 months. International Prostate Symptom Score (IPSS), maximum urinary flow rate (Qmax), post-void residual urine (PVR), International Index of Erectile Function-5 (IIEF-5), and Male Sexual Health Questionnaire for Ejaculatory Dysfunction Short Form (MSHQ-EjD) were obtained preoperatively and throughout follow-up. Paired t-test and Wilcoxon signed rank test were used for parametric and non-parametric parameters, respectively. RESULTS: IPSS quality of life (QoL) and total score significantly improved postoperatively and sustained during 3 months (4.5±1.0 vs. 3.3±1.7, P=0.002/19.6±6.3 vs. 14.6±8.6, P=0.018, respectively). Voiding symptoms improved (11.9±4.7 vs. 7.6±5.3, P=0.004), while store symptoms remained unchanged. Qmax and PVR did not change by PUL (10.4±4.7 vs. 11.0±6.1, P=0.300/45.2±64.0 vs. 39.1±35.0, P=0.550). Sexual function was stable or improved, particularly, in regards of confidence, rigidity for penetration and ejaculatory function (2.08±1.2 vs. 2.4±1.2, P=0.050/1.7±1.6 vs. 2.0±1.6, P=0.035/MSHQ-EjD: 10.6±4.6 vs. 9.3±4.9, P=0.040). Most of the adverse events [dysuria: 4 (14.8%), hematuria: 2 (14.8%), urinary retention: 2 (7.4%)] resolved within one or two days. Prostatic abscess occurred to a patient after weeks of the procedure, however, patient fully recovered through transurethral abscess drainage without implants removal. CONCLUSIONS: Our results suggest that PUL is safe and effective in improving LUTS and QoL. It also preserved or even improved sexual functions. The efficacies of PUL sustained during our follow up duration. PUL offers viable option for men with LUTS who desire to maintain sexual function with little adverse events. Further long-term follow up study is warranted.
format Online
Article
Text
id pubmed-6186654
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-61866542018-10-26 AB064. The efficacy of UroLift in Korean men with benign prostatic hyperplasia: preserving sexual function and improving lower urinary tract symptoms Tae, Sun Moon, Du Geon Kim, Je Jong Kim, Sang Woo Transl Androl Urol Printed Abstract BACKGROUND: Prostatic urethral lift (PUL) using UroLift is new and promising in the treatment of men with lower urinary tract symptoms (LUTS). It has been recently released for clinical use in Korea. This study is to report the initial experience and outcomes of the METHODS: Between December 2016 and November 2017, 31 patients with LUTS due to benign prostatic hyperplasia (BPH) either who were high risk for anesthesia, or wanting to preserve their sexual function, were treated with PUL. Patients were followed up for 3 months. International Prostate Symptom Score (IPSS), maximum urinary flow rate (Qmax), post-void residual urine (PVR), International Index of Erectile Function-5 (IIEF-5), and Male Sexual Health Questionnaire for Ejaculatory Dysfunction Short Form (MSHQ-EjD) were obtained preoperatively and throughout follow-up. Paired t-test and Wilcoxon signed rank test were used for parametric and non-parametric parameters, respectively. RESULTS: IPSS quality of life (QoL) and total score significantly improved postoperatively and sustained during 3 months (4.5±1.0 vs. 3.3±1.7, P=0.002/19.6±6.3 vs. 14.6±8.6, P=0.018, respectively). Voiding symptoms improved (11.9±4.7 vs. 7.6±5.3, P=0.004), while store symptoms remained unchanged. Qmax and PVR did not change by PUL (10.4±4.7 vs. 11.0±6.1, P=0.300/45.2±64.0 vs. 39.1±35.0, P=0.550). Sexual function was stable or improved, particularly, in regards of confidence, rigidity for penetration and ejaculatory function (2.08±1.2 vs. 2.4±1.2, P=0.050/1.7±1.6 vs. 2.0±1.6, P=0.035/MSHQ-EjD: 10.6±4.6 vs. 9.3±4.9, P=0.040). Most of the adverse events [dysuria: 4 (14.8%), hematuria: 2 (14.8%), urinary retention: 2 (7.4%)] resolved within one or two days. Prostatic abscess occurred to a patient after weeks of the procedure, however, patient fully recovered through transurethral abscess drainage without implants removal. CONCLUSIONS: Our results suggest that PUL is safe and effective in improving LUTS and QoL. It also preserved or even improved sexual functions. The efficacies of PUL sustained during our follow up duration. PUL offers viable option for men with LUTS who desire to maintain sexual function with little adverse events. Further long-term follow up study is warranted. AME Publishing Company 2018-09 /pmc/articles/PMC6186654/ http://dx.doi.org/10.21037/tau.2018.AB064 Text en 2018 Translational Andrology and Urology. All rights reserved.
spellingShingle Printed Abstract
Tae, Sun
Moon, Du Geon
Kim, Je Jong
Kim, Sang Woo
AB064. The efficacy of UroLift in Korean men with benign prostatic hyperplasia: preserving sexual function and improving lower urinary tract symptoms
title AB064. The efficacy of UroLift in Korean men with benign prostatic hyperplasia: preserving sexual function and improving lower urinary tract symptoms
title_full AB064. The efficacy of UroLift in Korean men with benign prostatic hyperplasia: preserving sexual function and improving lower urinary tract symptoms
title_fullStr AB064. The efficacy of UroLift in Korean men with benign prostatic hyperplasia: preserving sexual function and improving lower urinary tract symptoms
title_full_unstemmed AB064. The efficacy of UroLift in Korean men with benign prostatic hyperplasia: preserving sexual function and improving lower urinary tract symptoms
title_short AB064. The efficacy of UroLift in Korean men with benign prostatic hyperplasia: preserving sexual function and improving lower urinary tract symptoms
title_sort ab064. the efficacy of urolift in korean men with benign prostatic hyperplasia: preserving sexual function and improving lower urinary tract symptoms
topic Printed Abstract
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6186654/
http://dx.doi.org/10.21037/tau.2018.AB064
work_keys_str_mv AT taesun ab064theefficacyofuroliftinkoreanmenwithbenignprostatichyperplasiapreservingsexualfunctionandimprovinglowerurinarytractsymptoms
AT moondugeon ab064theefficacyofuroliftinkoreanmenwithbenignprostatichyperplasiapreservingsexualfunctionandimprovinglowerurinarytractsymptoms
AT kimjejong ab064theefficacyofuroliftinkoreanmenwithbenignprostatichyperplasiapreservingsexualfunctionandimprovinglowerurinarytractsymptoms
AT kimsangwoo ab064theefficacyofuroliftinkoreanmenwithbenignprostatichyperplasiapreservingsexualfunctionandimprovinglowerurinarytractsymptoms